Maraviroc Amarox Limited

Maraviroc, the active ingredient in Maraviroc Amarox Limited, is a CCR5 antagonist presented as an oral tablet for oral use. It is used in combination with other antiretroviral agents to treat HIV-1 infection in adults. GNH USA supplies Maraviroc Amarox Limited as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Maraviroc is a CCR5‑targeting antiretroviral indicated for specific HIV‑1 treatment scenarios. - HIV‑1 infection (treatment‑experienced): added to a regimen of other antiretrovirals to achieve viral suppression. - CCR5‑tropic HIV‑1 infection: prescribed when the virus uses the CCR5 co‑receptor, confirmed by tropism testing. - Combination antiretroviral therapy: incorporated into multi‑drug regimens to reduce HIV viral load and improve immune recovery.

Adverse reactions may vary in frequency and severity.

Common Side Effects: - Headache: mild to moderate intensity, often transient. - Nausea: occasional, may improve with food. - Diarrhea: watery stools, usually self‑limiting. - Fatigue: generalized tiredness. - Cough: dry or productive, non‑specific.

Serious or Rare Side Effects: - Hepatotoxicity: elevated liver enzymes or hepatitis. - Severe allergic reaction: rash, angioedema, or anaphylaxis. - QT interval prolongation: cardiac conduction changes. - Stevens‑Johnson syndrome/toxic epidermal necrolysis: severe skin reactions. - Immune reconstitution inflammatory syndrome: worsening of opportunistic infections after immune recovery.

Before initiating therapy, clinicians should evaluate patient‑specific factors and monitor for potential risks. - Liver function monitoring: assess baseline enzymes and repeat periodically. - CCR5 tropism testing: confirm virus uses CCR5 before prescribing. - Avoid strong CYP3A4 inducers: may reduce drug exposure and efficacy. - Pregnancy and breastfeeding: safety not established; weigh benefits against risks. - Cardiovascular assessment: caution in patients with pre‑existing heart disease. - Store at below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Maraviroc may interact with other medicines that affect its metabolism or transport.

Major Interactions (Avoid): - Rifampin: strong CYP3A4 inducer that markedly lowers maraviroc levels. - Carbamazepine: induces CYP3A4, reducing antiviral efficacy. - St. John’s wort: herbal inducer leading to decreased plasma concentrations.

Moderate Interactions (Monitor Closely): - Protease inhibitors (e.g., atazanavir): CYP3A4 inhibitors that can increase maraviroc exposure. - Azole antifungals (e.g., ketoconazole): may raise drug levels, requiring dose adjustment. - Macrolide antibiotics (e.g., erythromycin): can elevate plasma concentrations, necessitating monitoring.